Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
Condition: COVID-19 Intervention: Biological: Recombinant Novel Coronavirus vaccine (CHO Cells) Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
Condition: COVID-19 Intervention: Biological: Recombinant Novel Coronavirus vaccine (CHO Cells) Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
Condition: COVID-19 Intervention: Biological: Recombinant Novel Coronavirus vaccine (CHO Cells) Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Safety Study of COVID19 Vaccine on the Market
Condition: COVID-19 Intervention: Biological: Recombinant new coronavirus vaccine (CHO cell) Sponsors: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.; Hunan Provincial Center for Disease Control and Prevention; Guizhou Center for Disease Control and Prevention; Hainan Center for Disease Control & Prevention Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2023 Category: Research Source Type: clinical trials
